Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;43(8):1579-1587.
doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.

Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland

Aneta Guzek  1 , Zbigniew Rybicki  2 , Dariusz Tomaszewski  3 , Katarzyna Mackiewicz  1 , Wiesław Piechota  4 , Andrzej Chciałowski  5
Affiliations
Review

Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland

Aneta Guzek et al. Eur J Clin Microbiol Infect Dis. 2024 Aug.

Abstract

Purpose: Amongst all etiologic hospital-acquired infection factors, K. pneumoniae strains producing New Delhi metallo-β-lactamase (KP-NDM) belong to pathogens with the most effective antibiotic resistance mechanisms. Clinical guidelines recommend using ceftazidime/avibactam with aztreonam (CZA + AT) as the preferred option for NDM-producing Enterobacterales. However, the number of observations on such treatment regimen is limited. This retrospective study reports the clinical and microbiological outcomes of 23 patients with KP-NDM hospital-acquired infection treated with CZA + AT at a single center in Poland.

Methods: The isolates were derived from the urine, lungs, blood, peritoneal cavity, wounds, and peritonsillar abscess. In microbiological analysis, mass spectrometry for pathogen identification, polymerase chain reaction, or an immunochromatographic assay for detection of carbapenemase, as well as VITEK-2 system, broth microdilution, and microdilution in agar method for antimicrobial susceptibility tests were used, depending of the pathogens' nature. CZA was administered intravenously (IV) at 2.5 g every eight hours in patients with normal kidney function, and aztreonam was administered at 2 g every eight hours IV. Such dosage was modified when renal function was reduced.

Results: KP-NDM was eradicated in all cases. Four patients (17.4%) died: three of them had a neoplastic disease, and one - a COVID-19 infection.

Conclusion: The combination of CZA + AT is a safe and effective therapy for infections caused by KP-NDM, both at the clinical and microbiological levels. The synergistic action of all compounds resulted in a good agreement between the clinical efficacy of CZA + AT and the results of in vitro susceptibility testing.

Keywords: Avibactam, Ceftazidime drug combination; Aztreonam; Beta-lactamases; Klebsiella pneumoniae.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Centers for Diseases Control and Prevention (2019) Antibiotics resistance threats in the United States, 2019. [ https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed March 8, 2024
    1. World Health Organization (2022) Global antimicrobial resistance and use surveillance system (GLASS) report 2022. [ https://www.who.int/publications/i/item/9789240062702. Accessed March 8, 2024
    1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Lindsay Grayson M, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318–327. 10.1016/S1473-3099(17)30753-3 10.1016/S1473-3099(17)30753-3 - DOI - PubMed
    1. Calderon-Gonzalez R, Lee A, Lopez-Campos G, Hancock SJ, Sa-Pessoa J, Dumigan A, McMullan R, Campbell EL, Bengoechea JA (2023) Modelling the gastrointestinal carriage of Klebsiella pneumoniae infections. mBio 14(1):e0312122. 10.1128/mbio.03121-22 10.1128/mbio.03121-22 - DOI - PMC - PubMed
    1. Osorio J, Barreto J, Samboni CF, Cándelo LA, Alvarez LC, Benavidez S, Téllez RP, SantofimioD, Ramos JA, Gómez CA (2017) [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia]. Rev Chil Infectol 34(1):7–13. 10.4067/S0716-1018201700010000110.4067/S0716-10182017000100001 - DOI - PubMed

MeSH terms

LinkOut - more resources